DiaMedica Therapeutics In... (DMAC)
| Bid | 6.09 |
| Market Cap | 261.48M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.56 |
| PE Ratio (ttm) | -10.92 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.14 |
| Volume | 52,241 |
| Avg. Volume (20D) | 105,874 |
| Open | 5.89 |
| Previous Close | 6.06 |
| Day's Range | 5.64 - 6.15 |
| 52-Week Range | 2.14 - 6.41 |
| Beta | undefined |
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic ...
Analyst Forecast
According to 3 analyst ratings, the average rating for DMAC stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 14.47% from the latest price.
2 months ago · seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call TranscriptDiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer & Director Scott Kellen - ...
